Dr. Allison S. Fanelli, DO Pediatrics Medicare: Medicare Enrolled Practice Location: 789 E. Lancaster Ave., Suite 10, Villanova, PA 19085 Phone: 484-381-4010 Fax: 484-381-4020 |
Dr. John Goldener, M.D. Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 217 Radnor Chester Rd, Villanova, PA 19085 Phone: 610-525-5200 |
Samuel Shaw Fager, MD Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 1415 Old Gulph Rd, Villanova, PA 19085 Phone: 610-520-0246 Fax: 610-525-3737 |
Dr. Lauren Ann Kostelnik, Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 789 E Lancaster Ave Ste 10, Villanova, PA 19085 Phone: 484-381-4010 |
Dr. Gity Banan Etemad, M.D. Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 15 Wistar Rd, Villanova, PA 19085 Phone: 484-433-2339 |
News Archive
A new study in Behavioral Ecology, published by Oxford University Press, finds that women are less likely to procreate in urban areas that have a higher percentage of females than males in the population.
In 2012, four-year-old Bertrand Might became the first-ever patient diagnosed with a rare genetic disorder called N-glycanase (NGLY1) deficiency. The discovery of this condition and Bertrand's diagnosis allowed doctors to look for other children with the same genetic defect. Since then, more than 60 additional patients have been found.
What makes stem cells develop into kidneys? Lori O'Brien, a postdoctoral research associate in the laboratory of Andy McMahon, has received the first Broad Fellowship to help answer this question.
As previously disclosed, Sun Pharmaceutical Industries, Ltd. And Sun Pharma Global, Inc. (collectively, "Sun Pharma"), which own 75.8% of Caraco Pharmaceutical Laboratories, Ltd. common stock, have proposed (the "Proposal") a "going private" transaction by which Sun Pharma would acquire all of the outstanding shares of Caraco common stock not held by Sun Pharma for a per share consideration of $4.75 cash.
Adocia, a biotechnology company specializing in the development of ‘best-in-class' medicines from already approved therapeutic proteins, announced today that it had agreed with Eli Lilly and Company not to continue further joint research under the licensing agreement signed in December 2011 relating to use of Adocia's BioChaperone(R) technology for the formulation of fast acting insulin analog formulated with the BioChaperone(R) technology. Consequently, the two companies have terminated the collaboration.
› Verified 9 days ago